Today Sponge acquired
This article was originally published in The Tan Sheet
Executive Summary
Synova Healthcare Group purchases Allendale Pharmaceuticals, Inc. and the attendant exclusive worldwide rights to the Today Sponge contraceptive product, in an all-stock transaction for 16 million shares of Synova common stock, the firm announces Jan. 16. The API acquisition complements the firm's ongoing strategy of developing its women's health product portfolio, Synova states. The sponge currently retails for $7.99 per three-pack at drug store retailers nationwide. The company is planning a relaunch of the Today Sponge product accompanied by an "aggressive multimedia advertising campaign in the coming weeks," the Media, Pa.-based firm says. The product also will be cross-merchandised with Synova's Fem-V test kit, a panty-liner that tests vaginal discharge pH levels for bacterial infections, "as both products are targeted toward the same consumer audience," the firm states...
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.